Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03834688
Recruitment Status : Active, not recruiting
First Posted : February 8, 2019
Last Update Posted : November 14, 2022
Genentech, Inc.
Information provided by (Responsible Party):

Brief Summary:

Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion.

Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die.

The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.

Condition or disease Intervention/treatment Phase
Mantle Cell Lymphoma Drug: Venetoclax Drug: Bendamustine Drug: Rituximab Phase 2

Detailed Description:

Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin Lymphoma (NHL) which is considered incurable with conventional therapy. With an incidence of approximately 70,000 cases diagnosed in the United States (US) per year, the disease is rare.

This is an open-label phase II study of venetoclax in combination with bendamustine and rituximab. Patients will receive induction therapy with venetoclax, bendamustine and rituximab for six cycles (1 cycle = 28 days). There will be an interim analysis after 19 patients are enrolled to evaluate for tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells which can lead to electrolyte and kidney problems.

Tumor assessments will be performed after Cycle 3-4 and at end of induction therapy.

Mandatory pre-treatment tumor tissue sample (i.e., obtained in the course of standard biopsy or surgery) will be required for research (if sufficient tissue is available).

Mandatory bone marrow aspirate (obtained in the course of standard biopsy) and peripheral blood sample will be collected at the end of treatment for Minimal Residual Disease (MRD). MRD measures the disease remaining after treatment. Optional peripheral blood samples will also be collected for future research.

10/11/2021: Due to slower than anticipated enrollment, the study was redesigned to reflect the current historical complete response rate and with a lowered sample size for prompt primary endpoint readout.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-Label, Single-Arm Study, Cycle 1 Dose Escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Actual Study Start Date : January 13, 2020
Actual Primary Completion Date : October 20, 2022
Estimated Study Completion Date : November 2024

Arm Intervention/treatment
Experimental: Induction
Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
Drug: Venetoclax

Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)

Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days).

Other Names:
  • GDC-0199
  • ABT-199
  • RO5537382

Drug: Bendamustine
Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
Other Name: Bendamustine hydrochloride

Drug: Rituximab
Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
Other Names:
  • Chimeric anti-CD20 monoclonal antibody
  • Rituxan

Primary Outcome Measures :
  1. Complete Response (CR) rate at end of induction [ Time Frame: 8 months ]
    CR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 8 months ]
    Number of participants with abnormal laboratory values and/or adverse events with particular attention to TLS related to treatment

  2. Overall Response Rate (ORR) [ Time Frame: 8 months ]
    ORR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)

  3. Progression-Free Survival (PFS) [ Time Frame: 57 months ]
    PFS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)

  4. Overall Survival (OS) [ Time Frame: 57 months ]
    OS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL), with documented cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH.
  • Patients must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension.
  • Age ≥ 60 years.
  • No intention to undergo consolidation with high dose chemotherapy and autologous stem cell rescue (Autologous Stem Cell Transplant) in first remission.
  • ECOG performance status of 0-2.
  • Ability to understand and willingness to sign Institutional Review Board (IRB)-approved informed consent.
  • Willing to provide mandatory tissue samples (if sufficient tissue available), bone marrow and blood samples for research purposes.
  • Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks prior to registration:

    • Absolute Neutrophil Count (ANC) ≥ 1000/mm³
    • Hemoglobin ≥ 8 g/dL
    • Platelets ˃75,000/mm³
    • Creatinine clearance ≥ 40 mL/min, calculated with the use of 24-hour creatinine clearance or by Cockcroft-Gault formula
    • Total Bilirubin ≤ 1.5x Upper Limit of Normal (ULN) or ≤ 3x ULN for patients with documented Gilbert's syndrome
    • Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN
  • All females of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.
  • Women must not be pregnant or breastfeeding. Females of childbearing potential who are sexually active with a non-sterilized male partner and sexually active men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) prior to study entry, for the duration of study participation, and for 12 months after last dose of therapy. Method of contraception must be documented.
  • Patients should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma.
  • Patients must have no recent (<1 year) history of malignancy except for the following:

    • adequately treated non-melanoma skin cancer
    • adequately treated Stage I melanoma of the skin
    • in situ cervical cancer
    • low grade prostate adenocarcinoma (Gleason grade ≤ 6) managed with observation and stable for 6 months.
  • Patients should not have known evidence of central nervous system (CNS) lymphoma.
  • Patients must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication.
  • Patients must have no active, uncontrolled infections.
  • Patients must not have active hepatitis B or be chronic carriers of hepatitis B. This is defined as patients with hepatitis B surface antigen (HBsAg) positive. Patients with prior exposure to hepatitis B (hepatitis B core antibody (anti-HBc) positive AND HBsAg negative) are allowed with a protective level hepatitis B surface antibody AND a negative hepatitis B viral load by polymerase-chain reaction (PCR).
  • Patients must not have active hepatitis C (HCV) as defined by a hepatitis C viral load detectable by PCR. Patients with a negative HCV antibody are assumed to have a negative HCV viral load. Patients with a positive HCV antibody must have a negative hepatitis C viral load by PCR. Prior treatment for an active HCV infection will be allowed as long as the hepatitis C viral load by PCR is negative.
  • Patients must not have known active Human Immunodeficiency Virus (HIV). Testing not required in absence of clinical suspicion.
  • Patients must not have evidence of significant, uncontrolled concomitant diseases, including psychiatric diseases, that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient.
  • Patients must not have conditions that preclude oral administration or absorption of medications through the GI tract, including but not limited to the inability to swallow pills or malabsorption syndromes.
  • Patients must not have known allergies to both xanthine oxidase inhibitors and rasburicase.
  • Patients must not require the use of warfarin. Blood thinners of other classes are permitted.
  • Patient may not receive the following agents within 7 days prior to the first dose of venetoclax:

    • Strong and moderate CYP3A inhibitors
    • Strong and moderate CYP3A inducers
    • Strong and moderate P-gp inhibitors
  • Patients must not have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03834688

Layout table for location information
United States, Illinois
Carle Cancer Center
Urbana, Illinois, United States, 61801
United States, Indiana
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Michigan
St. Joseph Mercy Hospital Cancer Care Center
Ann Arbor, Michigan, United States, 48106
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine Siteman Cancer Center
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
United States, Pennsylvania
Penn State Cancer Institute
Hershey, Pennsylvania, United States, 17033
Reading Hospital/McGlinn Cancer Institute
West Reading, Pennsylvania, United States, 19611
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22903
United States, Wisconsin
Gundersen Health System
La Crosse, Wisconsin, United States, 54601
Sponsors and Collaborators
Genentech, Inc.
Layout table for investigator information
Study Chair: Craig Portell, MD University of Virginia
Layout table for additonal information
Responsible Party: PrECOG, LLC. Identifier: NCT03834688    
Other Study ID Numbers: PrE0405
ML40551 ( Other Identifier: Genentech )
First Posted: February 8, 2019    Key Record Dates
Last Update Posted: November 14, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data is proprietary

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by PrECOG, LLC.:
Bcl-2 Family Protein Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Bendamustine Hydrochloride
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action